ECSP10010167A - Composiciones oftálmicas novedosas - Google Patents

Composiciones oftálmicas novedosas

Info

Publication number
ECSP10010167A
ECSP10010167A EC2010010167A ECSP10010167A ECSP10010167A EC SP10010167 A ECSP10010167 A EC SP10010167A EC 2010010167 A EC2010010167 A EC 2010010167A EC SP10010167 A ECSP10010167 A EC SP10010167A EC SP10010167 A ECSP10010167 A EC SP10010167A
Authority
EC
Ecuador
Prior art keywords
ophthalmic compositions
new ophthalmic
new
salts
pharmaceutically acceptable
Prior art date
Application number
EC2010010167A
Other languages
English (en)
Inventor
Ajay Jaysingh Khopade
Arindam Halder
Subhas Balaram Bhowmick
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of ECSP10010167A publication Critical patent/ECSP10010167A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica adecuada para uso oftálmico que comprende uno o más derivados o sales de prostaglandina, una cantidad estabilizante de polietilenglicol hidroxiestearato y un vehículo farmacéuticamente aceptable.
EC2010010167A 2007-10-16 2010-05-10 Composiciones oftálmicas novedosas ECSP10010167A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2061MU2007 2007-10-16

Publications (1)

Publication Number Publication Date
ECSP10010167A true ECSP10010167A (es) 2010-06-29

Family

ID=40824837

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010167A ECSP10010167A (es) 2007-10-16 2010-05-10 Composiciones oftálmicas novedosas

Country Status (18)

Country Link
US (2) US9629852B2 (es)
EP (1) EP2197449A4 (es)
JP (1) JP5646331B2 (es)
KR (1) KR101510185B1 (es)
CN (1) CN101835473B (es)
AU (1) AU2008344909B2 (es)
BR (1) BRPI0818459A2 (es)
CA (1) CA2702478C (es)
CO (1) CO6270384A2 (es)
EA (1) EA201070483A1 (es)
EC (1) ECSP10010167A (es)
IL (1) IL205095A0 (es)
MX (1) MX2010004211A (es)
NZ (1) NZ584555A (es)
SG (1) SG185273A1 (es)
UA (1) UA100393C2 (es)
WO (1) WO2009084021A2 (es)
ZA (1) ZA201002615B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2398443A2 (en) * 2009-02-20 2011-12-28 Micro Labs Limited Storage stable prostaglandin product
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US9907826B2 (en) * 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
HUE054006T2 (hu) 2011-12-28 2021-08-30 Chugai Pharmaceutical Co Ltd Eljárás peptid vegyület ciklizálására
EP2630952A1 (en) * 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
CN105012231A (zh) * 2014-04-30 2015-11-04 四川科伦药物研究院有限公司 一种包含PGF2α衍生物的稳定性良好的眼用制剂及其制备方法
EP4039250A1 (en) * 2016-12-28 2022-08-10 Chugai Seiyaku Kabushiki Kaisha Self-emulsifying drug formulation for improving membrane permeability of compound
JP2020523312A (ja) * 2017-06-08 2020-08-06 アイ・セラピーズ・エル・エル・シー 低用量ブリモニジンの組み合わせおよびその使用
TWI839364B (zh) * 2018-07-12 2024-04-21 法國商尼可斯股份有限公司 包含釋放一氧化氮的前列醯胺之眼用組成物
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
WO2020250252A1 (en) 2019-06-11 2020-12-17 Sifi S.P.A. Microemulsion compositions
US11400100B2 (en) 2019-12-11 2022-08-02 Somerset Therapeutics, Llc. Effective benzalkonium chloride-free bimatoprost ophthalmic compositions
WO2021199814A1 (ja) * 2020-03-31 2021-10-07 参天製薬株式会社 樹脂製容器に充填された銀塩含有眼科用水性組成物
CN116847841A (zh) * 2020-10-13 2023-10-03 伦茨治疗股份有限公司 稳定眼科药物的组合物和储存方法
WO2023091439A1 (en) 2021-11-17 2023-05-25 Lenz Therapeutics, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
JP2022120120A (ja) * 2022-06-13 2022-08-17 東亜薬品株式会社 眼科用水性組成物及びプロスタグランジンＦ２α誘導体の含量の低下を抑制する方法
JP2025528009A (ja) 2022-07-15 2025-08-26 ドーシ，プラフル 医薬品と薬剤などの不安定な構成要素の安定剤とを含むコンタクトレンズを作製及び使用する方法
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
CA2295512C (en) * 1998-07-14 2009-05-26 Alcon Laboratories, Inc. Prostaglandin product
KR100350179B1 (ko) * 1998-09-23 2002-08-27 구주제약주식회사 Ｓｅｄｄｓ로 제제화한 발기부전치료용 주입액제
JP3876355B2 (ja) * 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
JP4092507B2 (ja) * 2003-07-31 2008-05-28 参天製薬株式会社 プロスタグランジン含有製品
US20050049311A1 (en) * 2003-09-03 2005-03-03 Pharmacia & Upjohn Company Medicinal products comprising prostaglandin compositions and methods of packaging such compositions
ES2314354T3 (es) * 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
EP1827373B1 (en) * 2004-11-09 2008-12-03 Novagali Pharma SA Ophthalmic emulsions containing prostaglandins
JPWO2007105691A1 (ja) * 2006-03-13 2009-07-30 株式会社アールテック・ウエノ 水性組成物
CA2672973C (en) * 2006-12-21 2016-03-08 Novagali Pharma Sa Process for manufacturing ophthalmic oil-in-water emulsions
US20080234376A1 (en) * 2007-03-21 2008-09-25 Taiwan Liposome Company (A Taiwan Corporation) Emulsion composition comprising prostaglandin e1
FR2918891B1 (fr) * 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur

Also Published As

Publication number Publication date
US20100137432A1 (en) 2010-06-03
CA2702478A1 (en) 2009-07-09
NZ584555A (en) 2012-03-30
CA2702478C (en) 2014-12-09
US20150290216A1 (en) 2015-10-15
KR101510185B1 (ko) 2015-04-10
CO6270384A2 (es) 2011-04-20
ZA201002615B (en) 2010-12-29
US9629852B2 (en) 2017-04-25
WO2009084021A2 (en) 2009-07-09
SG185273A1 (en) 2012-11-29
CN101835473A (zh) 2010-09-15
EA201070483A1 (ru) 2010-10-29
KR20100087107A (ko) 2010-08-03
JP5646331B2 (ja) 2014-12-24
WO2009084021A3 (en) 2009-12-03
EP2197449A2 (en) 2010-06-23
US9539262B2 (en) 2017-01-10
JP2011508724A (ja) 2011-03-17
AU2008344909B2 (en) 2013-06-06
UA100393C2 (ru) 2012-12-25
AU2008344909A1 (en) 2009-07-09
BRPI0818459A2 (pt) 2015-04-14
EP2197449A4 (en) 2013-10-09
MX2010004211A (es) 2010-06-30
CN101835473B (zh) 2012-12-05
IL205095A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
ECSP10010167A (es) Composiciones oftálmicas novedosas
CO6341565A2 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
ECSP099721A (es) Inhibidores de cinasa p70 s6
DOP2010000259A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
CR20150045A (es) Inhibidores de hepatitis c
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
UY33075A (es) Derivados de ciclohexano y usos de los mismos
GEP201606555B (en) Compounds and compositions for modulating egfr activity
UY30912A1 (es) Derivados de 4-pirazol amidas conteniendo carboxi, sales farmacéuticamente aceptables de los mismo, composiciones farmacéuticas conteniéndolos, procesos de preparacion y uso.
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
UY32203A (es) Amino pirimidinas y su uso en terapia
CR11857A (es) Compuestos pirazolicos 436
DOP2010000323A (es) Pirimidin-5-carboxamidas sustituidas 281
GT200900192A (es) Derivados de imidazol como inhibidores de proteina de uso de cinesina (eg-5).-
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
CR10573A (es) Derivados del pirazol como inhibidores del citocromo p450
ECSP11011048A (es) Inhibidores de cinasa akt y p70 s6
CO2021010930A2 (es) Hidroxipiridoxazepinas como activadores de nrf2
SV2010003752A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
GT200600366A (es) Compuestos de imidazol sustituido como inhibidores de ksp